Rubicon Research Limited – Investor Presentation Summary

Key Operational Highlights

  • Revenue from Operations for Q1 FY27 stood at ₹5,343 Million, a 51.6% growth YoY (Q1 FY26: ₹3,525 Million).
  • USD revenue was $55 Million for Q1 FY27, up 32% YoY ($42 Million in Q1 FY26).
  • Top 5 products contributed 39% of revenue in Q1 FY27, compared to 39%/35%/30%/34% in Q4/Q3/Q2/Q1 FY26.
  • Top 10 products contributed 55% of revenue in Q1 FY27, compared to 57%/53%/51%/56% in Q4/Q3/Q2/Q1 FY26.
  • Received 2 product approvals in Q1 FY27. 88% of all approved products are commercialized (76 of 86 approved products as of 30 Jun 2026).
  • Specialty portfolio contributed 36% to gross profit for the quarter.
  • Key drivers: Focus on specialty/differentiated products, strong revenue visibility in coming quarters, and a robust pipeline.

Segment-wise Performance

Not Specified

Financial Highlights

Revenue: ₹5,343 Million (Q1 FY27)

Gross Profit: ₹3,543 Million (45.8% YoY growth)

Gross Margin: 67.7% (increased 140bps sequentially from 66.3% in Q4 FY26)

Operating Pre-R&D EBITDA: ₹1,871 Million

Pre-R&D EBITDA (%): 35.0%

R&D Expense: ₹580 Million (10.9% of revenue)

Operating EBITDA (A): ₹1,291 Million (63.2% YoY growth)

Operating EBITDA Margin (%): 24.2%

Other Income - recurring (B): ₹21 Million

EBITDA (A+B): ₹1,312 Million (64.6% YoY growth)

EBITDA Margin %: 24.6%

Other Income (one-off): ₹36 Million (Insurance claim received on goods lost in transit)

PBT: ₹1,104 Million (85.3% YoY growth)

PAT: ₹848 Million (95.8% YoY growth)

EPS (Fully diluted): ₹5.08 (82.2% YoY growth)

YoY/QoQ comparison:

  • Revenue growth of 51.6% YoY and 4.0% QoQ (from ₹5,139 Mn in Q4 FY26)
  • PAT growth of 95.8% YoY and 10.4% QoQ (from ₹768 Mn in Q4 FY26)
  • Operating EBITDA Margin improved to 24.2% from 22.4% YoY and 23.1% QoQ

Drivers of financial performance: Broad-based revenue growth, stable pricing, focus on specialty products, and tactical measures to improve gross margin mix.

Key Risks: Sharp increase in key input costs owing to prevailing geopolitical situation, sequential increase in employee costs due to annual increments.

Geographical Revenue Split

Domestic vs Export/Regional Revenue: Not Specified

Balance Sheet Snapshot (as of 30-Jun-26)

Total Equity: ₹13,913 Million

Borrowings: ₹3,272 Million

Sources of Funds: ₹17,186 Million

Fixed Assets: ₹7,966 Million

Net Non-current Assets / (Liabilities): ₹37 Million

Inventory (At Cost): ₹7,458 Million

Trade Receivables: ₹5,915 Million

Trade Payables & Other current Liabilities (net of assets): (₹6,598) Million

Net Working Capital: ₹6,775 Million

Capital Employed: ₹14,778 Million

Cash & Cash Equivalents: ₹2,408 Million

Application of Funds: ₹17,186 Million

Days of Net Working Capital: 114 days (vs 126 days on 31-Mar-26)

ROACE (Annualized, pre-tax): 36%

Financial Health Insights: Strong capital efficiency with 36% ROACE. Net Working Capital days improved to 114 from 126 sequentially.

Capex & Cash Flow Health

Capital Expenditure: Not specified for quarter, but ₹371 Mn Capex mentioned in cash flow context.

Free Cash Flow: Not Specified

Operating Cash Flow: Net cash flow generated from operating activities was ₹285 Million for Q1 FY27.

Net Debt Movement: Not Specified

Cash Flow Details (Q1 FY27):

  • Cash generated from operating activities: ₹452 Million
  • Net cash flow from operating activities: ₹285 Million (adversely affected by delay in receiving significant GST refunds)
  • Cash flows used in investing activities: (₹1,412) Million (includes utilization of Bank Deposits of ₹705 Mn, acquisition of Arinna ₹1,759 Mn & Capex of ₹371 Mn)
  • Cash flows from financing activities: ₹590 Million
  • Net increase in cash and cash equivalents: (₹536) Million

Investment Rationale: Acquisition of manufacturing facilities (Arinna, New Jersey) for capacity expansion and focus on specialty/high-value products.

Strategic & R&D Initiatives

Investments in Innovation: R&D expense of ₹580 Million (10.9% of revenue) in Q1 FY27. Focus on building capabilities in drug-device combinations (e.g., intra-nasal drug delivery). Acquired Impopharma (Toronto) for nasal & inhalation product development. Commissioned one of the largest single-site nasal spray capacities in the world.

Expected impact on growth: R&D spend is a lead indicator of future revenue. Incremental revenue multiple on lagging R&D spend has been on an increasing trend (5.5x based on Q1FY27 annualization). Strong visibility for FY29/30 & beyond.

Strategic Rationale: Evolving from a service provider to a specialty products company. Moving up the value chain with focus on specialty and high-value products. Building a strong branded platform through subsidiary Validus.

Industry Trends & Business Environment

Macro/Industry Trends: Prevailing geopolitical situation causing sharp increase in key input costs. US FDA's Quality Management Maturity (QMM) Program promoting quality management maturity at drug manufacturing establishments.

Impact on Company: Geopolitical situation pressured input costs, but company managed to increase GM% sequentially through tactical measures. Selected as one of only 9 sites globally to participate in US FDA's QMM program in 2024.

Management Commentary & Growth Outlook

Strategic Outlook: Company is preparing for a new phase of growth in the coming years. Strengthening key leadership with appointment of new CFO and transition of current CFO to Chief Commercial Officer role.

FY Guidance: Revised full-year FY27 Operating EBITDA margin guidance upwards to at least 23% (from earlier 22-23% range). Called out specific costs that would impact EBITDA margins in remaining quarters: ESOP costs of new ESOP scheme, Arinna upfront growth-enabler costs, pre-revenue costs at New Jersey and Pithampur plant.

Risks and Opportunities: Risks include cost pressures from geopolitical situation and planned investments. Opportunities include commercial ramp-up of new manufacturing facilities (Pithampur from Q1 CY27, New Jersey targeting CY2027) and strong revenue visibility from R&D pipeline.

Additional Headings

Manufacturing Update:

  • Pithampur Plant: US FDA inspection resulted in Form 483 with 2 procedural observations. Company filed response and received USFDA's approval of a regulatory filing post-inspection. On track for commercial ramp-up from Q1 CY27.
  • New Jersey Facility: Acquired USFDA approved facility in East Brunswick for $2.9 Mn. Site has VAI (Voluntary Action Indicated) status after May-26 inspection. Targeting commercialization in CY 2027.

Leadership Changes:

  • Nitin Jajodia (current CFO) to move to Chief Commercial Officer (CCO) role upon successful transition.
  • Rohit Saraogi joined as CFO (Designate).

#CompanyName: Rubicon Research Limited